Haleon PLC

H6D0

Company Profile

  • Business description

    Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon’s brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.

  • Contact

    The Heights
    Building 5, First Floor
    WeybridgeSurreyKT13 0NY
    GBR

    T: +44 1932959500

    E: [email protected]

    https://www.haleon.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    24,524

Stocks News & Analysis

stocks

Eli Lilly receives FDA approval to add another oral GLP-1 to market

Wide moat Eli Lilly receives FDA approval for obesity pill.
stocks

Our top ASX picks in every sector

These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks

Which of the 3 giant AI IPOs should you buy?

OpenAI, Anthropic, and Databricks are expected to go public this year at massive valuations.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,864.8034.90-0.39%
CAC 407,981.27164.332.10%
DAX 4023,298.89618.852.73%
Dow JONES (US)46,565.74224.230.48%
FTSE 10010,364.79188.341.85%
HKSE25,254.4939.54-0.16%
NASDAQ21,840.95250.321.16%
Nikkei 22553,395.13344.55-0.64%
NZX 50 Index12,912.1086.230.67%
S&P 5006,575.3246.800.72%
S&P/ASX 2008,661.8023.20-0.27%
SSE Composite Index3,948.550.000.00%

Market Movers